Clinical Trial

Pelacarsen Roll-over Extension Program

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-03-12; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-30
Trial Details
NCT Number NCT06875973
Lead Sponsor Novartis Pharmaceuticals
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 599 participants
Start Date 2025-05-19
Primary Completion 2030-12-08 (estimated)
Study Completion 2030-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29